Navigation Links
GDFII/L&P Sucralose Win Over Competitor Tate & Lyle
Date:4/7/2009

EXETER, Calif., April 7 /PRNewswire/ -- Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington, D.C. ruled in its favor in a Section 337 patent dispute (docket no. 337-TA-604) filed against the company by its competitor, Tate & Lyle Corporation (T&L).

Mr. Wang Sanyong, a corporate officer of GDFII/L&P, comments, "This has been a long process but we are very pleased with the outcome and that we have been vindicated after a thorough review by the Commission. The final determination by the ITC continues to reaffirm to our dedicated customers the strength and innovation of our technology and processes, and the integrity of our company. We are pleased that our technological achievements have been recognized in these proceedings before the ITC."

The U.S. ITC governs investigations into allegations of unfair trade practices and has ruled in its final determination that GDFII/L&P has not violated any of the patents asserted in this Section 337 dispute.

This final ruling confirms the initial determination issued by Administrative Law Judge Charles E. Bullock of the ITC in September 2008 that there is no violation of Section 337 by GDFII/L&P. Judge Bullock found that GDFII/L&P did not infringe any of the asserted T&L patents and that one of the patents was also invalid. T&L appealed that initial ruling and the ITC approved a full review by the Commission.

Roger Matkin, CEO/President of Ingredients Specialties, Inc. (ISI), a strategic marketing and distribution partner to GDFII/L&P, notes, "We congratulate GDFII/L&P for this hard fought victory and recognize our attorneys with the Bingham McCutchen firm, led by Washington, D.C. partner Gary Hnath, who have represented GDFII/L&P so skillfully and diligently throughout the proceedings before the ITC. Gary and his team presented the facts to the ITC as fully and completely as possible." Roger continues, "After 2 years of a careful and thorough review by the ITC, the Commission has now presented its definitive finding on behalf of GDFII/L&P."

"This is welcome news for us, especially since many potential customers have held back in ordering product until confirmation of the positive ruling by the ITC," observed Mr. Bassam Faress, Director of Sales & Marketing at ISI and spokesperson for L&P. "We can confidently assure our network of global distributors and customers that GDFII/L&P is one of a few companies whose manufacturing processes have been fully and thoroughly reviewed by the U.S. ITC and that our Zueit(R) brand Sucralose has been determined to be non-infringing. This is very important to keep in mind as it may not be the case with other competitors now in the market."

Mr. Wang Ximin, a corporate officer of GDFII/L&P adds, "With this important victory now achieved, we are determined to aggressively expand our production of Sucralose and to position GDFII/L&P to more fully meet the anticipated high market demand for Sucralose globally."

Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) is a specialty ingredients manufacturer that pioneered the development and manufacturing of Sucralose at its ISO 9001:2000 and HACCP certified facility in China. Its alliance with Ingredient Specialties, Inc. of Exeter, California provides a global distribution network that markets Zueit(R) brand Sucralose (www.Zueit.com) to the food, beverage, nutraceutical and pharmaceutical industries as a Kosher and Halal certified non-caloric high intensity sweetener. Zueit(R) is a trademark of Ingredient Specialties, Inc. Exeter, CA, U.S.A.

*(LOGO 72dpi: Send2Press.com/mediaboom/09-0406-ZueitLG_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SENOMYX RECEIVES GENERALLY RECOGNIZED AS SAFE (GRAS) DETERMINATION FOR S2383 SUCRALOSE ENHANCER
2. CollaborateMD Offers Upgrade Program to Competitors' Users
3. LPGA Competitors and Friends Come Together for Breast Cancer
4. Perr&Knight Announces Discounted Fee Schedule for Access to Its Online Database of Commercial Lines Competitor Filings
5. Best Practices, LLC Announces New Benchmarking Study - How World-Class Companies Proactively Manage Competitors
6. Ironman Competitor with Diabetes Encourages Others to Live Without Limits; Competes in Ironman Arizona in Tempe
7. VNUS Medicals Patent Lawsuit Against Laser Competitors to Proceed to Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, RN, ... the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coalition ... muscular dystrophy, and funding for Duchenne research, participated in the April 25 U.S. ... Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott Conference Center in ...
(Date:4/29/2016)... ... 29, 2016 , ... The Society for Assisted Reproductive Technology ... required to report in vitro fertilization (IVF) delivery rates to both ... of assisted reproductive technologies in the United States. , This year, SART’s ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... The ... the workforce is aging – meaning that there is an urgent need for highly ... and interactive training solution, delivering a multi-pronged approach to train and retain care managers, ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
Breaking Medicine Technology: